Skip to main content

Table 2 Risk of UGIB and perforation associated with aspirin use

From: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

  All cases Controls Adjusted RR*
  (N=2,105) (N=11,500) (95%CI)
Non-use 1,696 10,157 1 (reference)
Current use (1-30) 287 837 2.0 (1.7-2.3)
   Use within 1-7 259 771 2.0 (1.7-2.3)
   days time window    
   Use within 8-30 28 66 2.3 (1.4-3.7)
   days time window    
Recent use (31-180) 37 123 1.5 (1.0-2.3)
   Use within 31-60 14 45 1.7 (0.9-3.3)
   days time window    
   Use within 61-180 23 78 1.5 (0.9-2.5)
   days time window    
Past use (>180) 85 383 1.1 (0.8-1.4)
  1. * Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol.